Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

53.69 -1.07 (-1.96%)
Streaming Delayed Price Updated: 3:29 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Praxis Precision Medicines stock fluctuated after reporting mixed results for their drug vormatrigine in treating focal onset seizures. 
Via Benzinga
Praxis (PRAX) Q2 Loss Widens 90%
Via The Motley Fool
Praxis Precision Medicines (NASDAQ:PRAX) Posts Q2 2025 Results with Strong Clinical Progress on Vormatrigine
Praxis Precision Medicines (PRAX) reports Q2 2025 results, highlighting strong clinical data for epilepsy drug vormatrigine with 56.3% seizure reduction. EPS beats estimates, stock rises pre-market. 
Via Chartmill
Earnings Scheduled For August 4, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
What to Expect from Praxis Precision Medicine's Earnings
 
Via Benzinga
Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts
 
Via Benzinga
The Analyst Verdict: Praxis Precision Medicine In The Eyes Of 4 Experts
 
Via Benzinga
Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts
 
Via Benzinga
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside
Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine. 
Via Benzinga
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Assessing Praxis Precision Medicine: Insights From 8 Financial Analysts
 
Via Benzinga
Expert Ratings For Praxis Precision Medicine
 
Via Benzinga
Forecasting The Future: 14 Analyst Projections For Praxis Precision Medicine
 
Via Benzinga
What 6 Analyst Ratings Have To Say About Praxis Precision Medicine
 
Via Benzinga
Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings)
 
Via Benzinga
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate
Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025. 
Via Benzinga
Keep an eye on the top gainers and losers in Friday's session.
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
Friday's session: top gainers and losers
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
These stocks are gapping in today's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday. 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Philip Morris International To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug
Praxis Precision Medicines reports positive Phase 2 EMBOLD study results for relutrigine in treating SCN2A and SCN8A developmental and epileptic encephalopathy, showing significant seizure reduction... 
Via Benzinga
These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results
 
Via Benzinga
PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Misses Revenue for Q2 2024
PRAX stock results show that Praxis Precision Medicine beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Are We Having Fun Yet? Stocks Sell Off On Massive Volume
In this video, I review the overall market, my game-plan with the indices, how our largest swings are holding up, and the stocks on my radar. 
Via Talk Markets
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
The companies are no longer developing their drug for essential tremor treatment. 
Via Investor's Business Daily
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.